Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in the $15 billion animal health market Evaluation of AZD5658 expands Conduit’s glucokinase activator platform into novel veterinary applications, complementing AZD1656 development Cost-efficient approach enhances Conduit’s pipeline while preserving... Read More

NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 22, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announces that, following confirmation of compliance with the Bid Price and Equity Requirements as detailed in the announcement dated May 21, 2025, the Company... Read More

Conduit regains compliance with Bid Price and Equity Requirements CDT will continue to be listed and traded on The Nasdaq Stock Market NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 21, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announced that the Company... Read More

NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announces that its board of directors has approved a 1-for-15 reverse stock split of the Company’s common stock. The Company’s stockholders approved the reverse... Read More

Conduit secures a composition of matter patent from the Korean Intellectual Property Office for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships. NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 09, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals", "Conduit" or the... Read More

New patent filing secures composition of matter protection for AZD5904, a potent myeloperoxidase inhibitor in Conduit’s pipeline, unlocking up to 20 years of new IP runway and enabling enhanced formulation strategies to target a broad range of diseases. NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 08, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals", "Conduit" or the... Read More

NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 16, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (" Conduit Pharmaceuticals " or " Conduit " or the " Company ") today announced key leadership changes to support the company’s next phase of growth and execution. Dr. Andrew Regan, the founder and initial financial backer of Conduit Pharmaceuticals, has been appointed Chief Executive Officer. He will... Read More

Conduit Pharmaceuticals files next generation cocrystal patent for VTAMA ® (tapinarof) which the Company believes could be a superior asset with both inflammatory and autoimmune prospectives just as the drug approaches 2027 exclusivity expiration, positioning the Company for high-value licensing partnerships. NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 11, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq:... Read More

NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 10, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (" Conduit " or the “ Company ”) today announced that its Board of Directors has authorized a share repurchase program under which the Company may purchase up to $1,000,000 of its outstanding common stock. The Directors believe that the market price of its common stock trades at prices that do not reflect... Read More

Conduit expands its partnership with Sarborg to apply advanced machine learning-driven analysis on clinical data from its AstraZeneca-acquired assets, aiming to uncover new insights and optimize development pathways. NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announces that it has... Read More

Conduit secures a composition of matter patent from the USPTO for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships. NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 31, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc . (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announces that... Read More

Conduit Pharmaceuticals advances its pipeline with key progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, formulation optimization, and IP expansion, positioning the Company for near-term milestones and growth. NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 19, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“ Conduit Pharmaceuticals ” or “ Conduit ” or the “... Read More

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 06, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) announces that, on February 11, 2025, the Company presented its plan of compliance to The Nasdaq Stock Market LLC ("Nasdaq”) Hearing Panel (the "Panel”) and requested an extension of time to achieve compliance with Nasdaq Listing Rules 5450(a)(1),... Read More

Collaboration reinforces Conduit’s commitment to leveraging AI and cybernetics to reduce human error, lower costs, and accelerate timelines in drug development Sarborg delivers a prototype AI-product to Conduit’s Management team NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“ Conduit ” or the “ Company ”), is pleased to announce the completion of the... Read More

Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing Charles River’s immunology expertise to refine study parameters and improve probability of successful Phase II clinical trial outcomes. The study aims to accelerate the development of AZD1656 (and its derivatives), for autoimmune disorders, with a focus on Systemic Lupus Erythematosus... Read More

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“ Conduit ” or the “ Company ”), today announces the repayment of its $600,000 promissory note (the “ Note ”) to Nirland Limited (“ Nirland ”) and provided an update on the conversion of its Senior Secured Promissory Note (the “ Senior Note ”) with Nirland. On February 7, 2025, Conduit repaid the final... Read More

Conduit and Sarborg complete all milestones of Phase I of their AI-driven drug development collaboration, and commence transitioning to Phase II, which will focus on developing personalized software dashboards to enhance efficiency, decision-making, and operational agility of its current and future portfolio NAPLES, Fla. and CAMBRIDGE, United Kingdom, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq:... Read More

Conduit is planning how to effectively integrate an advanced platform-driven approach powered by artificial intelligence and cybernetics to expedite drug development, while continuing to advance its portfolio of proprietary assets to clinic. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“ Conduit ” or the “ Company ”), today is pleased to announce... Read More

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound development, announces that its board of directors has approved a 1-for-100 reverse stock split of the Company’s common stock. The Company’s stockholders approved... Read More

Award-winning Agility Life Sciences brings a proven track record in drug formulation for a number of pharmaceutical and biotechnology clients. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“ Conduit ” or the “ Company ”), today announced that it has entered into a strategic services agreement with formulation development CDMO Agility Life Sciences (“... Read More

Conduit Pharmaceuticals partners with SARBORG Limited to leverage artificial intelligence and cybernetics for optimizing key drug development processes, including drug repurposing, discovery, and clinical trial monitoring. This innovative approach aims to reduce human error, cut costs, and improve efficiency, positioning Conduit for success across its current and future portfolio. NAPLES, Fla. and CAMBRIDGE, United Kingdom,... Read More

NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced that the Japan Patent Office (JPO) has granted approval of a composition of matter patent application for the Company’s lead asset, AZD1656, a Glucokinase Activator targeting a wide range of autoimmune disorders. This approval... Read More

Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30 years of experience in asset management, capital markets, and strategy development. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a multi-asset, clinical stage, disease-agnostic... Read More

Conduit Pharmaceuticals announces new addition to its autoimmune pipeline, underscored by composition of matter patent filing to strengthen its competitive position This new asset, CDT1656, combines AZD1656 with a second known-compound that has demonstrated immune-modulating effects across multiple autoimmune conditions, enhancing its therapeutic potential The addition of CDT1656 and the supporting composition of matter... Read More

SAN DIEGO and LONDON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced the restructuring of a portion of its financial obligations, enhancing its balance sheet and liquidity. The Company has restructured the $2.65 million loan note with Nirland Limited (“Nirland”) and secured $1.2 million in new promissory notes through separate agreements with third... Read More

SAN DIEGO and LONDON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced it will be participating in the H.C. Wainwright 26 th Annual Global Investment Conference, being held September 9-11, 2024. Dr. David Tapolczay, Founder and CEO of Conduit, will give a virtual presentation available on-demand starting on September 9 th at 7:00 am ET/12:00 pm BST.... Read More

Conduit Pharmaceuticals announces plans to initiate Phase 2a trials in both systemic lupus erythematosus and ANCA-associated vasculitis for its lead clinical candidate, AZD1656 AZD1656, a HK-4 glucokinase activator initially developed by AstraZeneca for diabetes, is now being repurposed by Conduit for autoimmune disorders, leveraging its established safety profile and targeted immune-modulating effects SAN DIEGO and LONDON,... Read More

Conduit Pharmaceuticals enters into exclusive license agreement with AstraZeneca for HK-4 Glucokinase activators AZD1656 and AZD5658 targeting autoimmune indications and myeloperoxidase inhibitor AZD5904 targeting idiopathic male infertility Assets have shown favorable preclinical and Phase I data. Conduit to initiate Phase II clinical trials SAN DIEGO and LONDON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals... Read More

SAN DIEGO and LONDON, July 16, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced the approval of a composition of matter patent application by IP Australia, achieving successful examination of a patent on its lead asset, an HK-4 Glucokinase Activator which targets a wide range of autoimmune diseases. The Company is enrolled to... Read More

SAN DIEGO and LONDON, June 13, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (the “Company” or “Conduit"), today announced the Company is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted by FTSE Russell on Friday,... Read More

Conduit also appoints prominent intellectual property attorney Jeffrey Lindeman as a Consultant Leadership additions underscore Conduit’s commitment to strengthening and broadening its intellectual property portfolio through solid-form technology to maximize future value SAN DIEGO and LONDON, March 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the... Read More

SAN DIEGO and LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit") today announced the opening of cutting-edge laboratory space in Cambridge, United Kingdom, a global centre for research and development for companies at the forefront of life science innovation. This strategic acquisition marks a pivotal milestone for Conduit, positioning the Company... Read More

SAN DIEGO and LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit"), a multi-asset, clinical-stage life science company delivering an efficient model for compound development, today announced CEO Dr. David Tapolczay, will be participating in the Oppenheimer 34th Annual Healthcare Life Sciences Conference, being held February 13-14, 2024. Dr. Tapolczay is scheduled to present on... Read More

SAN DIEGO and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit Pharmaceuticals” or “Conduit”), a multi-asset clinical-stage disease-agnostic life science company delivering an efficient model for compound development, today announced that its CEO, Dr. David Tapolczay, and its CFO, Adam Sragovicz, will be attending the 14th Annual Jefferies London Healthcare Conference, taking... Read More